Paul J Maddon

Progenics Pharmaceuticals, Inc.

$8,313,643

Attributed

$8,313,643

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$8,313,643 · 6

By mechanism

R01$5,702,764 · 2

R44$2,307,328 · 2

R43$303,551 · 1

N01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Progenics Pharmaceuticals, Inc.

Same institution · by research overlap

William C Olson$17,385,230
Daniel C Pevear$8,250,851
Dangshe Ma$5,789,789
Gerald P Donovan$9,061,908
Bryan M O'Hara$600,638

Others in their field

Top investigators on “Monoclonal Antibody”

Bambra Strokes · Ppd Development Lp$461,655,950
Glenda E Gray · Wits Health Consortium (Pty), Ltd$276,346,332
Lawrence Corey · Fred Hutchinson Cancer Center$271,417,082
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$257,261,947
Peter B. Gilbert · Fred Hutchinson Cancer Center$190,281,881
Barton F Haynes · Duke University$125,632,198

Research focus

Monoclonal AntibodyImmunological SubstanceAids TherapyAntiaids AgentDrug Screening /EvaluationHuman Immunodeficiency Virus 1Drug Design /Synthesis /ProductionClinical ResearchAntigen Antibody ReactionChemokineClinical Trial Phase ICombination TherapyHiv Envelope Protein Gp120Human SubjectHuman Therapy EvaluationImmunoglobulin GNeutralizing AntibodyPassive ImmunizationVirus ReceptorsHuman Immunodeficiency VirusVirus Infection MechanismPharmacokineticsMacacaCytokine Receptors